Replies to post #3521 on Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

I received this "ALERT" from my broker's news service this morning. No further info has been presented even though it stated "more to follow".
Just a headline but it reads:
News for 'HALO' - (*DJ Halozyme Therapeutics is Currently Investigating PEGPH20 in a Phase 2 Study of Metastatic Pancreatic Cancer)
Is this a new development?
Good luck!
-Fritz

[friendofthedevil]

Looks like I still have my shirt - barely.

The PDF titled Agenda on the conference website shows Thompson as the last speaker in a 15 min time slot presenting a "late breaking" abstract. To me, this implies new data on the 1b trial. Looking forward to it.

[rod5247]

"PEGPH20 plus gemcitabine was well tolerated and showed promising efficacy in patients with high tumor HA, leading to the current clinical phase 2 study of PEGPH20 in combination with nab-paclitaxel and gemcitabine for the treatment of stage IV PDA."

What would prevent him from discussing data from the first year of the Phase II study?